Advertisement

Digestive Diseases and Sciences

, Volume 57, Issue 10, pp 2535–2544 | Cite as

RETRACTED ARTICLE: Membrane-Bound Mucins and Mucin Terminal Glycans Expression in Idiopathic or Helicobacter pylori, NSAID Associated Peptic Ulcers

  • Yaron NivEmail author
  • Doron Boltin
  • Marisa Halpern
  • Miriam Cohen
  • Zohar Levi
  • Alex Vilkin
  • Sara Morgenstern
  • Vahig Manugian
  • Erica St. Lawrence
  • Pascal Gagneux
  • Surinder K. Batra
  • Samuel B. Ho
Original Article

Abstract

Background

The ratio of Helicobacter pylori/NSAID-negative gastric ulcers is increasing. Idiopathic gastric ulcers have unique clinical and endoscopic features, and are associated with more bleeding complications and a higher mortality. Alterations in gastric mucin expression and sialylation pattern may be important in ulcer pathogenesis.

Aims

The purpose of this study was to determine the expression pattern of membrane-bound mucins and side chain sugars in H. pylori associated-, NSAID-, and idiopathic-gastric ulcers.

Methods

We randomly selected 92 patients with H. pylori (group 1, n = 30), NSAID (group 2, n = 18), combined H. pylori and NSAID associated gastric ulcers (group 3, n = 24), and patients with idiopathic gastric ulcers (group 4, n = 20). Immunohistochemistry for T-cell CD4/CD8, MUC1, MUC4, MUC17, and ECA and SNA lectins staining was performed on sections from the ulcer margins. Inflammation score was assessed according to the Sydney system.

Results

Bleeding and mortality rates were significantly higher in group 4. CD4 positive T cell count was higher in H. pylori positive patients (P = 0.009). Staining intensity of MUC17 was higher in group 1 than in group 4, foveola and glands alike, with 11.50 ± 3.47 versus 6.80 ± 4.02, and 9.61 ± 4.26 versus 7.59 ± 3.26, respectively (P < 0.0001). This was a mirror image with MUC1. SNA lectin staining was increased in group 4, in parallel to MUC1 expression, indicating more abundant α2-6 sialylation in that group.

Conclusions

Cytoplasmic MUC17 staining was significantly decreased in the cases with idiopathic ulcer. The opposite was demonstrated for MUC1. This observation might be important, since different mucins with altered sialylation patterns likely differ in their protection efficiency against acid and pepsin.

Keywords

Idiopathic ulcer Mucin MUC1 MUC4 MUC17 SNA ECA Helicobacter pylori 

Notes

Acknowledgments

The work was supported by National Institute of Neurological Disorders and Stroke (grant P30 NS047101; Neurosciences Microscopy Shared Facility, UCSD) and grant *** CSD018 from the G. Harold and Leila Y. Mathers Charitable Foundation (P. Gagneux). Sukhwinder Kaur, Srustidhar Das, and Poonam Sharma performed the MUC4 staining.

Conflict of interest

None declared.

References

  1. 1.
    Hyvarinen H, Salmenkyla S, Sipponen P. Helicobacter pylori-negative duodenal and pyloric ulcer: role of NSAIDs. Digestion. 1996;57:305–309.PubMedCrossRefGoogle Scholar
  2. 2.
    Gisbert J, Blanco M, Mateos JM, et al. H. pylori -negative duodenal ulcer prevalence and causes in 774 patients. Dig Dis Sci. 1999;44:2295–2302.PubMedCrossRefGoogle Scholar
  3. 3.
    Tsuji H, Kohli Y, Fukumitsu S, et al. Helicobacter pylori-negative gastric and duodenal ulcers. J Gastroenterol. 1999;34:455–460.PubMedCrossRefGoogle Scholar
  4. 4.
    Elitsur Y, Lawrence Z. Non-Helicobacter pylori related duodenal ulcer disease in children. Helicobacter. 2001;6:239–243.PubMedCrossRefGoogle Scholar
  5. 5.
    McColl KEL, E-Nujumi AM, Chittajallu RS, et al. A study of the pathogenesis of Helicobacter pylori negative chronic duodenal ulceration. Gut. 1993;34:762–768.PubMedCrossRefGoogle Scholar
  6. 6.
    Jyotheeswaran S, Shah AN, Jin HO, et al. Prevalence of Helicobacter pylori in peptic ulcer patients in greater Rochester, NY: is empirical triple therapy justified? Am J Gastroenterol. 1998;93:574–578.PubMedCrossRefGoogle Scholar
  7. 7.
    Niv YH. pylori/NSAID—negative peptic ulcer—the mucin theory. Med Hypotheses. 2010;75:433–435.PubMedCrossRefGoogle Scholar
  8. 8.
    Ho SB, Takamura K, Anway R, et al. The adherent gastric mucous layer is composed of alternating layers of MUC5AC and MUC6 mucin proteins. Dig Dis Sci. 2004;49:1598–1606.PubMedCrossRefGoogle Scholar
  9. 9.
    Tanaka S, Mizuno M, Maga T, et al. H. pylori decreases gastric mucin synthesis via inhibition of galactosyltransferase. Hepatogastroenterol. 2003;50:1739–1742.Google Scholar
  10. 10.
    Kawakubo M, Ito Y, Okimura Y, et al. Natural antibiotic function of a human gastric mucin against Helicobacter pylori infection. Science. 2004;305:1003–1006.PubMedCrossRefGoogle Scholar
  11. 11.
    Niv Y, Boltin D, Vilkin A, et al. MUC5AC and MUC6 expression remains unchanged in H. pylori/NSAID—negative gastric ulcer (idiopathic ulcer). Gastroenterology. 2011;140:S732.Google Scholar
  12. 12.
    Luu Y, Junker W, Rachagani S, et al. Human intestinal MUC17 mucin augments intestinal cell restitution and enhances healing of experimental colitis. Int J Biochem Cell Biol. 2010;42:996–1006.PubMedCrossRefGoogle Scholar
  13. 13.
    Shibuya N, Goldstein IJ, Broekaert WF, et al. The elderberry (Sambucus nigra L.) bark lectin recognizes the Neu5Ac(alpha 2-6)Gal/GalNAc sequence. J Biol Chem. 1987;262:1596–1601.PubMedGoogle Scholar
  14. 14.
    De Boeck H, Loontiens FG, Lis H, et al. Binding of simple carbohydrates and some N-acetyllactosamine-containing oligosaccharides to Erythrina cristagalli agglutinin as followed with a fluorescent indicator ligand. Arch Biochem Biophys. 1984;234:297–304.PubMedCrossRefGoogle Scholar
  15. 15.
    Tsukashita S, Kushima R, Bamba M, et al. MUC gene expression and histogenesis of adenocarcinoma of the stomach. Int J Cancer. 2001;94:166–170.PubMedCrossRefGoogle Scholar
  16. 16.
    Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney System. International workshop on the histopathology of gastritis, Houston 1994. Am J Surg Pathol. 1996;20:1161–1181.PubMedCrossRefGoogle Scholar
  17. 17.
    Price AB. The Sydney system: histological division. J Gastroenterol Hepatol. 1991;6:209–222.PubMedCrossRefGoogle Scholar
  18. 18.
    Chan HL, Wu JC, Chan FK, et al. Is non-Helicobacter pylori, non-NSAID peptic ulcer a common cause of upper GI bleeding? A prospective study of 977 patients. Gastrointest Endosc. 2001;53:438–442.PubMedCrossRefGoogle Scholar
  19. 19.
    Xia HH, Wong BC, Wong KW, et al. Clinical and endoscopic characteristics of non-Helicobacter pylori, non-NSAID duodenal ulcers: a long-term prospective study. Aliment Pharmacol Ther. 2001;15:1875–1882.PubMedCrossRefGoogle Scholar
  20. 20.
    Wong GL, Wong VW, Chan Y, et al. High incidence of mortality and recurrent bleeding in patients with Helicobacter pylori-negative idiopathic bleeding ulcers. Gastroenterology. 2009;137:525–531.PubMedCrossRefGoogle Scholar
  21. 21.
    Gisbert JP, Calvet X. Review article: Helicobacter pylori-negative duodenal ulcer disease. Aliment Pharmacol Ther. 2009;30:791–815.PubMedCrossRefGoogle Scholar
  22. 22.
    McColl KE. How I manage H. pylori-negative, NSAID/aspirin-negative peptic ulcers. Am J Gastroenterol. 2009;104:190–193.PubMedCrossRefGoogle Scholar
  23. 23.
    Niv Y. MUC1 and colorectal cancer pathophysiology considerations. World J Gastro. 2008;14:2139–2141.CrossRefGoogle Scholar
  24. 24.
    Celli JP, Turner BS, Afdhal NH, et al. Helicobacter pylori moves through mucus by reducing mucin viscoelasticity. Proc Natl Acad Sci USA. 2009;106:14321–14326.PubMedCrossRefGoogle Scholar
  25. 25.
    Kobayashi M, Lee H, Nakayama J, et al. Roles of gastric mucin-type O-glycans in the pathogenesis of Helicobacter pylori infection. Glycobiology. 2009;19:453–461.PubMedCrossRefGoogle Scholar
  26. 26.
    Lindén S, Semino-Mora C, Liu H, et al. Role of mucin Lewis status in resistance to Helicobacter pylori infection in pediatric patients. Helicobacter. 2010;15:251–258.PubMedCrossRefGoogle Scholar
  27. 27.
    Stromberg E, Lundgren A, Edebo A, et al. Increased frequency of activated T-cells in the Helicobacter pylori-infected antrum and duodenum. FEMS Immunol Med Microbiol. 2003;36:159–168.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Yaron Niv
    • 1
    Email author
  • Doron Boltin
    • 1
  • Marisa Halpern
    • 2
  • Miriam Cohen
    • 3
  • Zohar Levi
    • 1
  • Alex Vilkin
    • 1
  • Sara Morgenstern
    • 4
  • Vahig Manugian
    • 5
    • 6
  • Erica St. Lawrence
    • 5
    • 6
  • Pascal Gagneux
    • 3
  • Surinder K. Batra
    • 7
  • Samuel B. Ho
    • 5
    • 6
  1. 1.Department of Gastroenterology, Rabin Medical CenterTel Aviv UniversityPetach TikvaIsrael
  2. 2.Department of Pathology, Rabin Medical CenterHasharon HospitalPetach TikvaIsrael
  3. 3.Department of Cellular and Molecular Medicine, Glycobiology Research and Training CenterUniversity of California at San DiegoSan DiegoUSA
  4. 4.Department of Pathology, Rabin Medical CenterBeilinson HospitalPetach TikvaIsrael
  5. 5.Department of MedicineUniversity of CaliforniaSan DiegoUSA
  6. 6.VA San Diego Healthcare SystemSan DiegoUSA
  7. 7.Department of Biochemistry and Molecular BiologyUniversity of NebraskaOmahaUSA

Personalised recommendations